A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Trial Profile

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 577
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 Jul 2017 Planned End Date changed from 1 Apr 2021 to 12 Oct 2024.
    • 03 Jul 2017 Planned primary completion date changed from 16 Apr 2020 to 5 Sep 2020.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top